Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal versus oral mefenamic acid for primary dysmenorrhoea
2007-001389-34Phase 2Completed
- Sponsor
- Plethora Solutions
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PSD508 and Mefenamic acid in primary dysmenorrhea (PD) (2 arms), sponsored by Plethora Solutions. Primary endpoint: Summed Pain Intensity Difference over 8 hours after first treatment. Started Oct 2007; status: completed.
02
Drugs
PSD508Mefenamic acid
03
Conditions
primary dysmenorrhea (PD)
Beyond the preview
Go deeper on 2007-001389-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001389-34.